Clinical trial:: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota
Clinical trial:: multispecies probiotic supplementation alleviates the symptoms of irritable bowel syndrome and stabilizes intestinal microbiota
复制标题
DOI：
10.1111/j.1365-2036.2007.03542.x
复制
发表时间：
2008-01-01
影响因子：
7.6
通讯作者：
Korpela, R.
中科院分区：
文献类型：
--
作者：
Kajander, K.;Myllyluoma, E.;Korpela, R.
背景肠易激综合征是消化科最常见的疾病。目的研究多种益生菌（鼠李糖乳杆菌GG、L. rhamnosus Lc 705、费氏丙酸杆菌亚种（Propionibacterium freudenreichii ssp.）shermanii JS和动物双歧杆菌亚种（Bifidobacterium animalis ssp.）Bb 12）对腹部症状、生活质量、肠道菌群和肠易激综合征炎症标志物的影响。MethodsEighty-six肠易激综合征患者（罗马11标准）参加了这一随机、安慰剂对照的5个月干预。患者被随机分配每天接受多种益生菌补充剂或安慰剂。监测肠易激综合征症状、生活质量、基于微阵列的肠道微生物群稳定性（n = 20）、血清细胞因子和敏感C反应蛋白。（95%CI：-19至-9）与安慰剂相比为3个点（95%CI：-8至1）（P = 0.0083）。尤其是腹胀和腹痛。观察到微生物群的稳定，因为微生物群相似性指数随着益生菌补充剂的增加而增加（1.9 +/- 3.1），而随着安慰剂的减少（-2.9 +/- 1.7）。C-反应蛋白.ConclusionsThis多物种益生菌似乎是一种有效和安全的选择，以减轻肠易激综合征的症状，并稳定肠道菌群。
BackgroundIrritable bowel syndrome is the most common diagnosis in gastroenterology. Trials suggest certain probiotics to be beneficial.AimTo investigate the effects of multispecies probiotic supplementation (Lactobacillus rhamnosus GG, L. rhamnosus Lc705, Propionibacterium freudenreichii ssp. shermanii JS and Bifidobacterium animalis ssp. lactis Bb 12) on abdominal symptoms, quality of life, intestinal microbiota and inflammatory markers in irritable bowel syndrome.MethodsEighty-six irritable bowel syndrome patients (Rome 11 criteria) participated in this randomized, placebo-controlled 5-month intervention. Patients were randomized to receive daily either multispecies probiotic supplementation or placebo. Irritable bowel syndrome symptoms, quality of life, microarray-based intestinal microbiota stability (n = 20), serum cytokines and sensitive C-reactive protein were monitored.ResultsThe composite irritable bowel syndrome score had at 5 months decreased 14 points (95% CI: -19 to -9) from baseline with the multispecies probiotic vs. three points (95% CI: -8 to 1) with placebo (P = 0.0083). Especially, distension and abdominal pain were affected. A stabilization of the microbiota was observed, as the microbiota similarity index increased with the probiotic supplementation (1.9 +/- 3.1), while it decreased with placebo (-2.9 +/- 1.7). No differences were seen in C-reactive protein.ConclusionsThis multispecies probiotic seems to be an effective and safe option to alleviate symptoms of irritable bowel syndrome, and to stabilize the intestinal microbiota.